Myotonic dystrophy

Myotonic dystrophy

Watch later

Watch later

Development of the muscular system
Erb-Duchenne palsy
Klumpke paralysis
Thoracic outlet syndrome
Muscles of the thoracic wall
Vessels and nerves of the thoracic wall
Winged scapula
Brachial plexus
Carpal tunnel syndrome
Anatomy clinical correlates: Wrist and hand
Vessels and nerves of the hand
Muscle weakness: Clinical
Vessels and nerves of the forearm
Muscles of the forearm
Anatomy clinical correlates: Median, ulnar and radial nerves
Muscles of the hand
Fascia, vessels and nerves of the upper limb
Baker cyst
Myotonic dystrophy
Bursitis
Unhappy triad
Meniscus tear
Superficial structures of the neck: Anterior triangle
Iliotibial band syndrome
Neurocutaneous disorders: Pathology review
Bones of the lower limb
Bones of the upper limb
Anatomy of the anterior and medial thigh
Necrotizing fasciitis
Skin cancer: Clinical
Bone tumors: Pathology review
Neuromuscular junction disorders: Pathology review
Legg-Calve-Perthes disease
Pediatric orthopedic conditions: Clinical
Restless legs syndrome
Anatomy of the leg
Osgood-Schlatter disease (traction apophysitis)
Developmental dysplasia of the hip
Anatomy of the hip joint
Anatomy of the orbit
Patellofemoral pain syndrome
Anatomy of the elbow joint
Joints of the ankle and foot
Femoral hernia
Achondroplasia
Lower back pain: Clinical
Osteoporosis
Osteoporosis medications
Back pain: Pathology review
Lordosis, kyphosis, and scoliosis
Osteopetrosis
Osteomalacia
Osteomalacia and rickets
Paget disease of bone
Acute tubular necrosis
Bones of the cranium
Bones of the neck
Pediatric bone tumors: Clinical
Bone histology
Bone remodeling and repair
Seronegative arthritis: Clinical
Seronegative and septic arthritis: Pathology review
Reactive arthritis
Juvenile idiopathic arthritis
Joint pain: Clinical
Gout
Gout and pseudogout: Pathology review
Non-steroidal anti-inflammatory drugs
Sjogren syndrome: Clinical
Sjogren syndrome
Sjogren syndrome: Pathology review
Pediatric bone and joint infections: Clinical
Pasteurella multocida
Bites and stings: Clinical
Spondylitis
Cauda equina syndrome
Systemic lupus erythematosus (SLE): Clinical
Skin and soft tissue infections: Clinical
Antiphospholipid syndrome
Systemic lupus erythematosus (SLE): Pathology review
Fibromyalgia
Myasthenia gravis
Lambert-Eaton myasthenic syndrome
Raynaud phenomenon
Cholinomimetics: Indirect agonists (anticholinesterases)
Scleroderma: Pathology review
Scleroderma
Skin histology
Skin cancer: Pathology review
Hypersensitivity skin reactions: Clinical
Hair, skin and nails
Acneiform skin disorders: Pathology review
Benign hyperpigmented skin lesions: Clinical
Pigmentation skin disorders: Pathology review
Blistering skin disorders: Clinical
Papulosquamous and inflammatory skin disorders: Pathology review
Vesiculobullous and desquamating skin disorders: Pathology review
Eczematous rashes: Clinical
Body focused repetitive disorders
Cellulitis
Seborrhoeic dermatitis
Malassezia (Tinea versicolor and Seborrhoeic dermatitis)
Atopic dermatitis
Contact dermatitis
Papulosquamous skin disorders: Clinical
Hypokinetic movement disorders: Clinical
Movement disorders: Pathology review
Actinic keratosis
Hypopigmentation skin disorders: Clinical
Angiosarcomas
Human herpesvirus 8 (Kaposi sarcoma)
Bartonella henselae (Cat-scratch disease and Bacillary angiomatosis)
Impetigo
Erysipelas
Orbital cellulitis
Periorbital cellulitis
Abscesses
Osteomyelitis
Periapical lesions
Staphylococcus aureus
Herpesvirus medications
Herpes simplex virus
Poxvirus (Smallpox and Molluscum contagiosum)
Varicella zoster virus
Epstein-Barr virus (Infectious mononucleosis)
Autoimmune bullous skin disorders: Clinical
Sarcoidosis
Pityriasis rosea
Rosacea
Sunburn
Burns: Clinical
Burns
Acetaminophen (Paracetamol)
Paracetamol toxicity
Bronchodilators: Leukotriene antagonists and methylxanthines
Cholinomimetics: Direct agonists
Skeletal muscle histology
Mechanisms of antibiotic resistance
Cell wall synthesis inhibitors: Penicillins
Cell wall synthesis inhibitors: Cephalosporins
DNA synthesis inhibitors: Fluoroquinolones
Miscellaneous protein synthesis inhibitors
Protein synthesis inhibitors: Tetracyclines
Miscellaneous cell wall synthesis inhibitors
Antituberculosis medications
Antimetabolites: Sulfonamides and trimethoprim
Protein synthesis inhibitors: Aminoglycosides
Integrase and entry inhibitors
Nucleoside reverse transcriptase inhibitors (NRTIs)
Protease inhibitors
Hepatitis medications
Non-nucleoside reverse transcriptase inhibitors (NNRTIs)
Neuraminidase inhibitors
Azoles
Echinocandins
Miscellaneous antifungal medications
Anthelmintic medications
Antimalarials
Anti-mite and louse medications

Transcript

Watch video only

With myotonic dystrophy, “myo” means muscle, “tonic” means spasm, “dys” means bad, and “troph” means nourish; so myotonic dystrophy refers to the muscle appearing poorly nourished and weak, and being contracted, without being able to relax.

Myotonic dystrophy is actually a group of disorders, all of which are caused by autosomal dominant genetic mutations.

This means that one affected copy of a gene is enough to cause disease.

Affected people are typically present in each generation, because an affected person (male or female) has a 50% chance of passing on the affected gene to a child, which causes that child to have the disease.

There are two major types of myotonic dystrophy: type 1, or DM1 for short, also known as Steinert’s disease and type 2, or DM2 for short.

In myotonic dystrophy type 1, the affected gene is on the long arm of chromosome 19 and is called DMPK.

The DMPK gene has a trinucleotide repeat, which means that a group of three DNA nucleotides is repeated multiple times in a row.

In DMPK, it’s the nucleotides cytosine, thymine, and guanine, or CTG.

These CTGs are found in the 3’ untranslated region of DMPK.

The 3’ untranslated region is at the end of the DMPK gene that’s made into mRNA but not protein, and it helps modulate gene expression.

Expressed DMPK mRNA gets translated into a protein called myotonic dystrophy protein kinase, and it helps in the communication between muscle cells, but also heart and brain cells.

In the muscle, this kinase shuts off a muscle protein called myosin phosphatase, which is involved in muscle tensing or contraction and relaxation.

In myotonic dystrophy type 2, the affected gene is located on the long arm of chromosome 3 and is called CNBP.

Instead of a trinucleotide repeat, the CNBP gene contains a tetranucleotide repeat where the nucleotides cytosine, cytosine, thymine, and guanine, or CCTG are repeated multiple times in a row.

These CCTGs are found in the first intron of CMBP, which is a part of the gene that’s made into mRNA but not protein, and helps modulate gene expression.

Expressed CNBP mRNA gets translated into a protein called Cellular nucleic acid- binding protein, which controls the function of various genes in the muscle and heart.

In both types of myotonic dystrophy, there is a repeat expansion, meaning there’s an increased number of CTG and CCTG repeats in the affected genes, respectively.

This repeat expansion is caused by slipped mispairing, which is where the enzyme DNA polymerase gets confused when copying a repetitive sequence.

DNA polymerase loses its place among the repeats and goes back to recopy what it already just copied.

This is like getting lost in a video and watch the same part over and over.

But since DNA polymerase is making copies, the effect is an increase, or expansion, of the number of repeats.

And once as a zygote develops into a fetus and eventually into a full adult, by the time sperm and eggs are created, several dozen cell divisions, each with a round of DNA replication have taken place, and so there have already been ample opportunities for repeat expansion, and the more repeats that’ re added, the more unstable it gets.

This expansion of the originally inherited gene means a child of a parent with myotonic dystrophy can inherit even more repeats than the parent did.

The higher the number of repeats in the protein, the earlier the age when a person starts having symptoms and the more severe these symptoms are.

This phenomenon is called anticipation, which means that families often show earlier symptom onset and increased severity with each generation.

Key Takeaways

Myotonic dystrophy is an autosomal dominant genetic disorder that is characterized by progressive muscle weakness and myotonia. Symptoms may include facial-muscle weakness, drooping eyelids, muscle stiffness, foot and hand contractures, cataracts, difficulty walking, and cardiac conduction defects. Treatment typically includes physical therapy, medications, and lifestyle modifications.